These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 24833067)
21. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials. Chen YH; Li C; Lan KK Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615 [TBL] [Abstract][Full Text] [Related]
22. Randomized phase II designs in cancer clinical trials: current status and future directions. Lee JJ; Feng L J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154 [TBL] [Abstract][Full Text] [Related]
23. Alternative designs for clinical trials in rare diseases. Abrahamyan L; Feldman BM; Tomlinson G; Faughnan ME; Johnson SR; Diamond IR; Gupta S Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):313-331. PubMed ID: 27862920 [TBL] [Abstract][Full Text] [Related]
24. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety. Teramukai S; Daimon T; Zohar S Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148 [TBL] [Abstract][Full Text] [Related]
25. Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach. Spann M; Lindborg S; Seaman J; Baker R; Dunayevich E; Breier A J Psychiatr Res; 2009 Feb; 43(5):561-7. PubMed ID: 18804218 [TBL] [Abstract][Full Text] [Related]
26. Sample-size calculations for trials that inform individual treatment decisions: a 'true-choice' approach. Girling AJ; Lilford RJ; Braunholtz DA; Gillett WR Clin Trials; 2007; 4(1):15-24. PubMed ID: 17327242 [TBL] [Abstract][Full Text] [Related]
27. Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting. Jazić I; Liu X; Laird G J Biopharm Stat; 2021 Jul; 31(4):507-522. PubMed ID: 34053399 [TBL] [Abstract][Full Text] [Related]
28. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Kidwell KM; Roychoudhury S; Wendelberger B; Scott J; Moroz T; Yin S; Majumder M; Zhong J; Huml RA; Miller V Orphanet J Rare Dis; 2022 May; 17(1):186. PubMed ID: 35526036 [TBL] [Abstract][Full Text] [Related]
29. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. Ben-Zvi I; Livneh A Isr Med Assoc J; 2014 May; 16(5):271-3. PubMed ID: 24979828 [TBL] [Abstract][Full Text] [Related]
30. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Xie F; Ji Y; Tremmel L Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247 [TBL] [Abstract][Full Text] [Related]
31. Characteristics and Public Availability of Results of Clinical Trials on Rare Diseases Registered at Clinicaltrials.gov. Dechartres A; Riveros C; Harroch M; Faber T; Ravaud P JAMA Intern Med; 2016 Apr; 176(4):556-8. PubMed ID: 26954340 [No Abstract] [Full Text] [Related]
32. The use of a registry database in clinical trial design: assessing the influence of entry criteria on statistical power and number of eligible patients. Peelen L; Peek N; de Jonge E; Scheffer GJ; de Keizer NF Int J Med Inform; 2007; 76(2-3):176-83. PubMed ID: 16829179 [TBL] [Abstract][Full Text] [Related]